25 XP   0   0   10

Chongqing Lummy Pharmaceutical
Buy, Hold or Sell?

Let's analyse Chongqing Lummy Pharmaceutical together

PenkeI guess you are interested in Chongqing Lummy Pharmaceutical. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Chongqing Lummy Pharmaceutical. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Chongqing Lummy Pharmaceutical

I send you an email if I find something interesting about Chongqing Lummy Pharmaceutical.

Quick analysis of Chongqing Lummy Pharmaceutical (30 sec.)










What can you expect buying and holding a share of Chongqing Lummy Pharmaceutical? (30 sec.)

How much money do you get?

How much money do you get?
¥0.01
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥2.01
Expected worth in 1 year
¥1.95
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
¥0.02
Return On Investment
0.7%

For what price can you sell your share?

Current Price per Share
¥2.69
Expected price per share
¥2.03 - ¥3.17
How sure are you?
50%

1. Valuation of Chongqing Lummy Pharmaceutical (5 min.)




Live pricePrice per Share (EOD)

¥2.69

Intrinsic Value Per Share

¥1.77 - ¥2.12

Total Value Per Share

¥3.78 - ¥4.13

2. Growth of Chongqing Lummy Pharmaceutical (5 min.)




Is Chongqing Lummy Pharmaceutical growing?

Current yearPrevious yearGrowGrow %
How rich?$292.8m$301.2m-$7.5m-2.6%

How much money is Chongqing Lummy Pharmaceutical making?

Current yearPrevious yearGrowGrow %
Making money-$307.9k-$2.3m$2m669.6%
Net Profit Margin-1.5%-8.6%--

How much money comes from the company's main activities?

3. Financial Health of Chongqing Lummy Pharmaceutical (5 min.)




What can you expect buying and holding a share of Chongqing Lummy Pharmaceutical? (5 min.)

Welcome investor! Chongqing Lummy Pharmaceutical's management wants to use your money to grow the business. In return you get a share of Chongqing Lummy Pharmaceutical.

What can you expect buying and holding a share of Chongqing Lummy Pharmaceutical?

First you should know what it really means to hold a share of Chongqing Lummy Pharmaceutical. And how you can make/lose money.

Speculation

The Price per Share of Chongqing Lummy Pharmaceutical is ¥2.69. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Chongqing Lummy Pharmaceutical.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Chongqing Lummy Pharmaceutical, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥2.01. Based on the TTM, the Book Value Change Per Share is ¥-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.02 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Chongqing Lummy Pharmaceutical.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.2%0.00-0.1%0.00-0.1%0.00-0.2%0.00-0.1%
Usd Book Value Change Per Share0.000.1%0.00-0.1%0.000.0%0.000.1%0.000.1%
Usd Dividend Per Share0.000.1%0.000.1%0.000.1%0.000.1%0.000.1%
Usd Total Gains Per Share0.010.2%0.000.0%0.000.0%0.010.2%0.010.3%
Usd Price Per Share0.51-0.52-0.59-0.73-1.67-
Price to Earnings Ratio21.54--574.64--12.81-4,161.98-2,330.97-
Price-to-Total Gains Ratio95.66-347.86-8.06-150.03-298.03-
Price to Book Ratio1.85-1.85-2.07-4.24-10.31-
Price-to-Total Gains Ratio95.66-347.86-8.06-150.03-298.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.37122
Number of shares2693
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.01
Gains per Quarter (2693 shares)1.6813.54
Gains per Year (2693 shares)6.7054.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
129-22-3262844
258-444525698
386-66117884152
4115-8818105112206
5144-11125131140260
6173-13332157168314
7202-15539183196368
8230-17746209224422
9259-19953235252476
10288-22160261280530

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%23.013.04.057.5%41.013.04.070.7%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%18.022.00.045.0%35.023.00.060.3%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%56.00.02.096.6%
Total Gains per Share3.01.00.075.0%7.05.00.058.3%11.09.00.055.0%28.012.00.070.0%46.012.00.079.3%

Fundamentals of Chongqing Lummy Pharmaceutical

About Chongqing Lummy Pharmaceutical

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company provides antibacterial, antifungal, antiviral agent, acid-base balance nutritional, liver auxiliary, Chinese patent, base large infusion drugs; American ginseng; and drugs for the treatment of tumors, as well as digestive, immune, blood, nervous, cardiovascular, and endocrinology systems. It also offers sodium bicarbonate injection. The company was founded in 1999 and is headquartered in Chongqing, China.

Fundamental data was last updated by Penke on 2024-04-16 11:22:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Chongqing Lummy Pharmaceutical.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Chongqing Lummy Pharmaceutical earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Chongqing Lummy Pharmaceutical to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 18.2% means that ¥0.18 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 18.2%. The company is making a huge profit. +2
  • The TTM is -1.5%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ18.2%TTM-1.5%+19.6%
TTM-1.5%YOY-8.6%+7.1%
TTM-1.5%5Y-8.1%+6.7%
5Y-8.1%10Y-1.8%-6.3%
1.1.2. Return on Assets

Shows how efficient Chongqing Lummy Pharmaceutical is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Chongqing Lummy Pharmaceutical to the Drug Manufacturers - General industry mean.
  • 1.6% Return on Assets means that Chongqing Lummy Pharmaceutical generated ¥0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 1.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is -0.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.6%TTM-0.1%+1.6%
TTM-0.1%YOY-0.6%+0.5%
TTM-0.1%5Y-1.1%+1.0%
5Y-1.1%10Y-0.3%-0.8%
1.1.3. Return on Equity

Shows how efficient Chongqing Lummy Pharmaceutical is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Chongqing Lummy Pharmaceutical to the Drug Manufacturers - General industry mean.
  • 2.2% Return on Equity means Chongqing Lummy Pharmaceutical generated ¥0.02 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 2.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -0.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ2.2%TTM-0.1%+2.3%
TTM-0.1%YOY-0.8%+0.7%
TTM-0.1%5Y-2.3%+2.2%
5Y-2.3%10Y-0.7%-1.6%

1.2. Operating Efficiency of Chongqing Lummy Pharmaceutical.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Chongqing Lummy Pharmaceutical is operating .

  • Measures how much profit Chongqing Lummy Pharmaceutical makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Chongqing Lummy Pharmaceutical to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.4%+0.4%
TTM-0.4%YOY-11.7%+11.3%
TTM-0.4%5Y-5.7%+5.3%
5Y-5.7%10Y-2.3%-3.4%
1.2.2. Operating Ratio

Measures how efficient Chongqing Lummy Pharmaceutical is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.41 means that the operating costs are ¥1.41 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 1.407. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.355. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.407TTM1.355+0.052
TTM1.355YOY1.334+0.021
TTM1.3555Y1.312+0.043
5Y1.31210Y0.976+0.336

1.3. Liquidity of Chongqing Lummy Pharmaceutical.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Chongqing Lummy Pharmaceutical is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 2.93 means the company has ¥2.93 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 2.928. The company is able to pay all its short-term debts. +1
  • The TTM is 2.681. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.928TTM2.681+0.247
TTM2.681YOY2.717-0.037
TTM2.6815Y2.022+0.658
5Y2.02210Y1.094+0.928
1.3.2. Quick Ratio

Measures if Chongqing Lummy Pharmaceutical is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Chongqing Lummy Pharmaceutical to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.58 means the company can pay off ¥0.58 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 0.575. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.907. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.575TTM0.907-0.331
TTM0.907YOY1.279-0.373
TTM0.9075Y0.864+0.043
5Y0.86410Y0.630+0.234

1.4. Solvency of Chongqing Lummy Pharmaceutical.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Chongqing Lummy Pharmaceutical assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Chongqing Lummy Pharmaceutical to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.27 means that Chongqing Lummy Pharmaceutical assets are financed with 26.6% credit (debt) and the remaining percentage (100% - 26.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 0.266. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.278. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.266TTM0.278-0.012
TTM0.278YOY0.279-0.001
TTM0.2785Y0.377-0.100
5Y0.37710Y0.412-0.035
1.4.2. Debt to Equity Ratio

Measures if Chongqing Lummy Pharmaceutical is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Chongqing Lummy Pharmaceutical to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 36.9% means that company has ¥0.37 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Chongqing Lummy Pharmaceutical:

  • The MRQ is 0.369. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.392. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.369TTM0.392-0.023
TTM0.392YOY0.397-0.005
TTM0.3925Y0.717-0.325
5Y0.71710Y0.802-0.085

2. Market Valuation of Chongqing Lummy Pharmaceutical

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Chongqing Lummy Pharmaceutical generates.

  • Above 15 is considered overpriced but always compare Chongqing Lummy Pharmaceutical to the Drug Manufacturers - General industry mean.
  • A PE ratio of 21.54 means the investor is paying ¥21.54 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Chongqing Lummy Pharmaceutical:

  • The EOD is 15.577. Based on the earnings, the company is fair priced.
  • The MRQ is 21.541. Based on the earnings, the company is fair priced.
  • The TTM is -574.636. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD15.577MRQ21.541-5.964
MRQ21.541TTM-574.636+596.177
TTM-574.636YOY-12.806-561.830
TTM-574.6365Y4,161.975-4,736.611
5Y4,161.97510Y2,330.972+1,831.004
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Chongqing Lummy Pharmaceutical:

  • The EOD is 25.016. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 34.595. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is -45.899. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD25.016MRQ34.595-9.579
MRQ34.595TTM-45.899+80.494
TTM-45.899YOY4.189-50.088
TTM-45.8995Y-642.672+596.773
5Y-642.67210Y-336.794-305.878
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Chongqing Lummy Pharmaceutical is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 1.85 means the investor is paying ¥1.85 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Chongqing Lummy Pharmaceutical:

  • The EOD is 1.338. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.851. Based on the equity, the company is underpriced. +1
  • The TTM is 1.854. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.338MRQ1.851-0.512
MRQ1.851TTM1.854-0.003
TTM1.854YOY2.068-0.213
TTM1.8545Y4.242-2.388
5Y4.24210Y10.312-6.070
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Chongqing Lummy Pharmaceutical compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.017-0.015+187%-0.006+138%0.019-9%0.024-27%
Book Value Per Share--2.0102.0150%2.067-3%1.800+12%1.599+26%
Current Ratio--2.9282.681+9%2.717+8%2.022+45%1.094+168%
Debt To Asset Ratio--0.2660.278-4%0.279-5%0.377-30%0.412-35%
Debt To Equity Ratio--0.3690.392-6%0.397-7%0.717-48%0.802-54%
Dividend Per Share--0.0220.019+12%0.011+98%0.018+24%0.026-16%
Eps--0.043-0.013+131%-0.016+138%-0.034+180%-0.011+125%
Free Cash Flow Per Share--0.0270.005+411%-0.003+110%0.020+33%0.017+61%
Free Cash Flow To Equity Per Share--0.027-0.014+150%0.037-27%0.021+28%0.024+10%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.900+11%
Intrinsic Value_10Y_max--2.119--------
Intrinsic Value_10Y_min--1.768--------
Intrinsic Value_1Y_max--0.053--------
Intrinsic Value_1Y_min--0.052--------
Intrinsic Value_3Y_max--0.280--------
Intrinsic Value_3Y_min--0.265--------
Intrinsic Value_5Y_max--0.654--------
Intrinsic Value_5Y_min--0.596--------
Market Cap2840397943.040-38%3927989682.6003946468128.6880%4511380623.363-13%7915249696.977-50%13927527219.561-72%
Net Profit Margin--0.182-0.015+108%-0.086+147%-0.081+145%-0.018+110%
Operating Margin----0.0040%-0.1170%-0.0570%-0.0230%
Operating Ratio--1.4071.355+4%1.334+5%1.312+7%0.976+44%
Pb Ratio1.338-38%1.8511.8540%2.068-10%4.242-56%10.312-82%
Pe Ratio15.577-38%21.541-574.636+2768%-12.806+159%4161.975-99%2330.972-99%
Price Per Share2.690-38%3.7203.7380%4.273-13%5.290-30%12.087-69%
Price To Free Cash Flow Ratio25.016-38%34.595-45.899+233%4.189+726%-642.672+1958%-336.794+1074%
Price To Total Gains Ratio69.175-38%95.662347.862-73%8.059+1087%150.025-36%298.030-68%
Quick Ratio--0.5750.907-37%1.279-55%0.864-33%0.630-9%
Return On Assets--0.016-0.001+104%-0.006+136%-0.011+167%-0.003+118%
Return On Equity--0.022-0.001+105%-0.008+137%-0.023+207%-0.007+133%
Total Gains Per Share--0.0390.005+762%0.005+754%0.036+7%0.049-21%
Usd Book Value--292858902.596293666264.8330%301215880.893-3%273066303.216+7%238330351.454+23%
Usd Book Value Change Per Share--0.002-0.002+187%-0.001+138%0.003-9%0.003-27%
Usd Book Value Per Share--0.2770.2780%0.285-3%0.248+12%0.221+26%
Usd Dividend Per Share--0.0030.003+12%0.002+98%0.002+24%0.004-16%
Usd Eps--0.006-0.002+131%-0.002+138%-0.005+180%-0.002+125%
Usd Free Cash Flow--3917210.155766318.428+411%-381249.798+110%2966865.121+32%1772614.752+121%
Usd Free Cash Flow Per Share--0.0040.001+411%0.000+110%0.003+33%0.002+61%
Usd Free Cash Flow To Equity Per Share--0.004-0.002+150%0.005-27%0.003+28%0.003+10%
Usd Market Cap391974916.140-38%542062576.199544612601.7590%622570526.024-13%1092304458.183-50%1921998756.299-72%
Usd Price Per Share0.371-38%0.5130.5160%0.590-13%0.730-30%1.668-69%
Usd Profit--6290933.159-307992.832+105%-2370464.618+138%-4554881.503+172%-1377585.614+122%
Usd Revenue--34615451.79930897946.957+12%30518243.775+13%44490815.693-22%41946394.865-17%
Usd Total Gains Per Share--0.0050.001+762%0.001+754%0.005+7%0.007-21%
 EOD+4 -4MRQTTM+23 -11YOY+22 -125Y+24 -1010Y+21 -14

3.2. Fundamental Score

Let's check the fundamental score of Chongqing Lummy Pharmaceutical based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.577
Price to Book Ratio (EOD)Between0-11.338
Net Profit Margin (MRQ)Greater than00.182
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.575
Current Ratio (MRQ)Greater than12.928
Debt to Asset Ratio (MRQ)Less than10.266
Debt to Equity Ratio (MRQ)Less than10.369
Return on Equity (MRQ)Greater than0.150.022
Return on Assets (MRQ)Greater than0.050.016
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Chongqing Lummy Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.521
Ma 20Greater thanMa 502.880
Ma 50Greater thanMa 1002.836
Ma 100Greater thanMa 2003.244
OpenGreater thanClose2.660
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Minority Interest  2223,7503,9721,0575,029-4,578451-8,813-8,362
Net Income  -31,33627,702-3,634-46,789-50,42349,966-45746,04345,586
Net Income from Continuing Operations  -31,55823,952-7,606-47,846-55,45254,543-90854,85753,948



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets2,890,880
Total Liabilities768,714
Total Stockholder Equity2,080,652
 As reported
Total Liabilities 768,714
Total Stockholder Equity+ 2,080,652
Total Assets = 2,890,880

Assets

Total Assets2,890,880
Total Current Assets1,646,171
Long-term Assets1,244,709
Total Current Assets
Cash And Cash Equivalents 836,437
Net Receivables 323,382
Inventory 170,997
Other Current Assets 3,584
Total Current Assets  (as reported)1,646,171
Total Current Assets  (calculated)1,334,399
+/- 311,771
Long-term Assets
Property Plant Equipment 286,968
Goodwill 32,943
Intangible Assets 211,996
Long-term Assets Other 60,192
Long-term Assets  (as reported)1,244,709
Long-term Assets  (calculated)592,098
+/- 652,611

Liabilities & Shareholders' Equity

Total Current Liabilities562,272
Long-term Liabilities206,441
Total Stockholder Equity2,080,652
Total Current Liabilities
Short Long Term Debt 113,500
Accounts payable 37,902
Other Current Liabilities 2,310
Total Current Liabilities  (as reported)562,272
Total Current Liabilities  (calculated)153,712
+/- 408,561
Long-term Liabilities
Long term Debt 126,500
Capital Lease Obligations Min Short Term Debt2,527
Long-term Liabilities Other 51,762
Long-term Liabilities  (as reported)206,441
Long-term Liabilities  (calculated)180,788
+/- 25,653
Total Stockholder Equity
Total Stockholder Equity (as reported)2,080,652
Total Stockholder Equity (calculated)0
+/- 2,080,652
Other
Capital Stock1,055,911
Common Stock Shares Outstanding 1,055,911
Net Invested Capital 2,320,652
Net Working Capital 1,083,898
Property Plant and Equipment Gross 286,968



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302008-12-312007-12-312006-12-31
> Total Assets 
125,104
214,687
268,557
285,700
672,815
653,626
674,025
706,642
726,832
884,010
954,854
1,038,777
1,047,465
1,080,985
1,116,337
1,374,340
1,415,896
1,423,720
1,954,893
2,044,836
2,199,588
2,182,135
2,251,996
2,276,227
2,205,577
2,243,898
2,480,675
2,554,795
2,500,703
3,102,764
2,598,889
2,580,574
2,587,167
2,484,109
2,619,747
2,699,044
2,854,212
2,740,346
2,950,575
3,033,256
3,097,158
3,140,778
3,539,234
3,605,602
3,602,892
3,501,431
3,424,776
3,475,390
3,603,193
3,147,803
3,663,070
3,093,213
2,979,180
2,926,774
3,008,326
3,005,383
3,037,979
3,054,985
3,083,794
2,920,717
2,891,885
2,890,880
2,890,8802,891,8852,920,7173,083,7943,054,9853,037,9793,005,3833,008,3262,926,7742,979,1803,093,2133,663,0703,147,8033,603,1933,475,3903,424,7763,501,4313,602,8923,605,6023,539,2343,140,7783,097,1583,033,2562,950,5752,740,3462,854,2122,699,0442,619,7472,484,1092,587,1672,580,5742,598,8893,102,7642,500,7032,554,7952,480,6752,243,8982,205,5772,276,2272,251,9962,182,1352,199,5882,044,8361,954,8931,423,7201,415,8961,374,3401,116,3371,080,9851,047,4651,038,777954,854884,010726,832706,642674,025653,626672,815285,700268,557214,687125,104
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,335,778
1,251,971
1,287,281
1,728,412
1,716,228
1,722,709
1,780,704
1,772,412
1,766,949
1,911,445
1,696,795
2,502,928
1,939,892
1,752,402
1,726,995
1,779,821
1,766,381
1,795,368
1,745,482
1,838,758
1,678,339
1,667,199
1,646,171
1,646,1711,667,1991,678,3391,838,7581,745,4821,795,3681,766,3811,779,8211,726,9951,752,4021,939,8922,502,9281,696,7951,911,4451,766,9491,772,4121,780,7041,722,7091,716,2281,728,4121,287,2811,251,9711,335,778000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
348,208
258,090
314,643
476,148
417,288
372,168
436,727
406,234
517,255
707,069
544,906
1,329,810
767,913
642,097
559,431
655,776
681,812
738,379
846,286
903,778
773,749
828,636
836,437
836,437828,636773,749903,778846,286738,379681,812655,776559,431642,097767,9131,329,810544,906707,069517,255406,234436,727372,168417,288476,148314,643258,090348,208000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
168
143
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001431680000000000000000000000000000000000000000000
       Net Receivables 
40,001
53,348
73,036
89,495
86,093
85,013
121,302
119,656
138,177
138,461
194,177
176,432
191,166
145,358
206,833
214,509
232,578
188,291
279,147
261,768
283,411
212,295
232,890
230,254
274,261
250,656
289,630
279,711
301,404
325,215
348,839
319,134
316,726
294,850
338,552
358,676
406,423
450,390
458,935
505,393
489,156
600,714
482,509
559,503
591,163
977,481
894,295
793,572
838,120
819,958
899,088
903,185
865,355
984,510
926,163
868,697
864,814
660,904
714,783
680,735
635,380
323,382
323,382635,380680,735714,783660,904864,814868,697926,163984,510865,355903,185899,088819,958838,120793,572894,295977,481591,163559,503482,509600,714489,156505,393458,935450,390406,423358,676338,552294,850316,726319,134348,839325,215301,404279,711289,630250,656274,261230,254232,890212,295283,411261,768279,147188,291232,578214,509206,833145,358191,166176,432194,177138,461138,177119,656121,30285,01386,09389,49573,03653,34840,001
       Inventory 
15,107
39,370
64,684
59,689
60,272
66,342
72,775
75,155
81,251
116,795
105,067
115,098
123,497
136,473
138,795
117,349
133,950
148,975
154,371
178,677
188,812
169,613
173,918
224,131
277,502
275,183
381,606
432,000
387,320
346,538
331,555
357,100
381,050
333,653
337,564
377,705
374,966
346,008
345,748
404,036
399,443
311,744
302,451
267,009
264,370
316,714
372,820
368,327
322,930
296,655
228,961
233,611
221,368
157,775
172,399
193,186
171,608
202,401
192,769
195,751
173,842
170,997
170,997173,842195,751192,769202,401171,608193,186172,399157,775221,368233,611228,961296,655322,930368,327372,820316,714264,370267,009302,451311,744399,443404,036345,748346,008374,966377,705337,564333,653381,050357,100331,555346,538387,320432,000381,606275,183277,502224,131173,918169,613188,812178,677154,371148,975133,950117,349138,795136,473123,497115,098105,067116,79581,25175,15572,77566,34260,27259,68964,68439,37015,107
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,810,821
1,889,374
1,880,183
1,720,727
1,652,364
1,708,440
1,691,749
1,451,008
1,160,142
1,153,320
1,226,778
1,199,779
1,228,505
1,239,002
1,242,611
1,309,503
1,245,036
1,242,378
1,224,686
1,244,709
1,244,7091,224,6861,242,3781,245,0361,309,5031,242,6111,239,0021,228,5051,199,7791,226,7781,153,3201,160,1421,451,0081,691,7491,708,4401,652,3641,720,7271,880,1831,889,3741,810,821000000000000000000000000000000000000000000
       Property Plant Equipment 
30,561
55,136
59,757
70,781
57,826
72,025
62,455
118,469
87,334
238,881
177,203
342,467
257,757
410,172
312,475
434,966
376,335
563,636
490,434
761,468
682,022
950,294
900,588
933,512
947,407
981,874
979,328
968,169
956,444
943,088
927,492
903,207
885,087
871,332
849,105
827,124
805,264
780,995
757,374
732,944
711,761
685,827
666,800
643,253
622,636
600,605
584,734
566,754
552,303
459,972
430,323
407,850
396,335
392,492
381,473
370,900
356,080
339,920
328,166
315,503
304,160
286,968
286,968304,160315,503328,166339,920356,080370,900381,473392,492396,335407,850430,323459,972552,303566,754584,734600,605622,636643,253666,800685,827711,761732,944757,374780,995805,264827,124849,105871,332885,087903,207927,492943,088956,444968,169979,328981,874947,407933,512900,588950,294682,022761,468490,434563,636376,335434,966312,475410,172257,757342,467177,203238,88187,334118,46962,45572,02557,82670,78159,75755,13630,561
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150,523
150,523
150,523
150,523
150,523
150,523
150,523
150,523
150,523
150,523
150,523
150,523
150,523
150,523
150,523
131,505
131,505
131,505
131,505
131,505
162,891
162,891
162,891
87,698
87,698
87,698
87,698
38,857
32,943
32,943
32,943
32,943
32,943
32,943
32,943
32,943
32,943
32,943
32,943
32,943
32,94332,94332,94332,94332,94332,94332,94332,94332,94332,94332,94332,94338,85787,69887,69887,69887,698162,891162,891162,891131,505131,505131,505131,505131,505150,523150,523150,523150,523150,523150,523150,523150,523150,523150,523150,523150,523150,523150,523150,5230000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
360,466
522,104
502,582
439,150
522,012
519,436
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000519,436522,012439,150502,582522,104360,466000000000000000000000000000000000000000
       Intangible Assets 
10,645
15,020
22,926
3,130
23,709
2,855
24,303
2,613
63,767
2,267
213,859
8,979
267,489
8,819
287,152
7,788
299,022
14,294
322,011
16,404
357,068
23,264
294,863
293,234
291,436
297,218
295,480
293,847
288,102
299,007
294,873
295,175
294,791
308,390
306,083
303,798
301,548
288,806
286,296
152,404
150,249
158,274
426,845
314,638
446,900
319,352
317,876
316,629
316,938
233,359
205,029
207,298
209,621
174,852
176,719
182,657
184,781
240,150
245,072
242,817
235,412
211,996
211,996235,412242,817245,072240,150184,781182,657176,719174,852209,621207,298205,029233,359316,938316,629317,876319,352446,900314,638426,845158,274150,249152,404286,296288,806301,548303,798306,083308,390294,791295,175294,873299,007288,102293,847295,480297,218291,436293,234294,86323,264357,06816,404322,01114,294299,0227,788287,1528,819267,4898,979213,8592,26763,7672,61324,3032,85523,7093,13022,92615,02010,645
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,824
49,433
43,613
133,103
85,001
24,359
577,706
6,988
5,663
5,231
5,813
4,322
7,283
11,953
33,604
48,600
45,286
45,264
48,836
60,192
60,19248,83645,26445,28648,60033,60411,9537,2834,3225,8135,2315,6636,988577,70624,35985,001133,10343,61349,43344,824000000000000000000000000000000000000000000
> Total Liabilities 
60,715
106,777
130,769
132,664
159,877
128,547
137,949
168,676
180,729
322,419
372,954
406,352
401,058
420,813
434,215
685,899
714,987
713,213
883,359
974,979
1,102,245
1,056,427
1,147,278
1,265,427
1,186,204
1,226,954
1,457,992
1,545,500
1,465,181
1,412,887
885,578
875,459
869,751
809,853
925,218
969,966
1,100,350
1,017,454
1,214,938
1,319,944
1,383,383
1,416,737
1,746,646
1,810,906
1,788,619
1,847,700
1,775,070
1,888,418
2,004,036
1,916,188
1,315,702
766,359
656,397
714,647
825,864
846,549
833,343
870,021
902,184
816,489
787,823
768,714
768,714787,823816,489902,184870,021833,343846,549825,864714,647656,397766,3591,315,7021,916,1882,004,0361,888,4181,775,0701,847,7001,788,6191,810,9061,746,6461,416,7371,383,3831,319,9441,214,9381,017,4541,100,350969,966925,218809,853869,751875,459885,5781,412,8871,465,1811,545,5001,457,9921,226,9541,186,2041,265,4271,147,2781,056,4271,102,245974,979883,359713,213714,987685,899434,215420,813401,058406,352372,954322,419180,729168,676137,949128,547159,877132,664130,769106,77760,715
   > Total Current Liabilities 
60,715
106,777
130,769
132,664
159,877
128,547
137,949
168,676
180,729
303,588
355,364
376,888
373,538
403,129
394,526
658,657
683,735
688,464
858,885
949,580
1,058,121
948,500
1,001,091
1,042,631
967,612
1,052,258
1,267,440
1,278,923
1,226,929
1,207,434
626,782
481,563
520,394
618,562
765,691
884,037
836,014
832,714
1,073,150
1,094,025
1,193,685
1,214,422
1,579,471
1,707,992
1,714,238
1,732,342
1,666,270
1,599,654
1,689,208
1,701,380
1,173,313
696,796
601,517
666,803
633,218
619,399
660,696
701,140
751,827
664,231
590,771
562,272
562,272590,771664,231751,827701,140660,696619,399633,218666,803601,517696,7961,173,3131,701,3801,689,2081,599,6541,666,2701,732,3421,714,2381,707,9921,579,4711,214,4221,193,6851,094,0251,073,150832,714836,014884,037765,691618,562520,394481,563626,7821,207,4341,226,9291,278,9231,267,4401,052,258967,6121,042,6311,001,091948,5001,058,121949,580858,885688,464683,735658,657394,526403,129373,538376,888355,364303,588180,729168,676137,949128,547159,877132,664130,769106,77760,715
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59,400
199,880
45,300
785,391
959,405
988,306
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000988,306959,405785,39145,300199,88059,400000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59,400
199,880
45,300
785,391
959,405
988,306
957,373
1,026,870
989,030
1,021,067
894,489
576,014
211,742
116,600
130,000
121,000
115,000
127,500
121,500
141,000
108,000
123,000
113,500
113,500123,000108,000141,000121,500127,500115,000121,000130,000116,600211,742576,014894,4891,021,067989,0301,026,870957,373988,306959,405785,39145,300199,88059,400000000000000000000000000000000000000000
       Accounts payable 
22,326
53,001
56,718
51,456
56,206
44,933
62,147
64,262
72,709
86,395
84,894
64,678
65,528
69,376
58,781
122,825
127,810
105,764
183,379
291,575
339,558
171,707
204,533
249,440
328,957
277,573
396,459
361,694
325,667
239,492
171,460
170,529
143,619
131,380
138,263
132,639
125,154
133,411
120,102
117,692
139,036
171,231
136,433
106,091
114,863
93,668
100,317
68,366
72,739
69,394
56,064
33,948
35,621
34,261
37,471
26,027
22,864
49,630
58,500
51,811
34,365
37,902
37,90234,36551,81158,50049,63022,86426,02737,47134,26135,62133,94856,06469,39472,73968,366100,31793,668114,863106,091136,433171,231139,036117,692120,102133,411125,154132,639138,263131,380143,619170,529171,460239,492325,667361,694396,459277,573328,957249,440204,533171,707339,558291,575183,379105,764127,810122,82558,78169,37665,52864,67884,89486,39572,70964,26262,14744,93356,20651,45656,71853,00122,326
       Other Current Liabilities 
8,389
20,676
26,751
24,038
28,681
29,214
23,332
23,304
31,520
90,693
82,440
92,680
37,510
56,142
40,745
175,928
173,403
240,400
236,206
106,705
210,563
227,589
113,126
124,767
100,674
118,995
94,680
94,283
152,997
98,060
89,502
67,232
76,306
99,337
118,498
122,057
112,732
138,795
111,479
101,290
140,345
75,869
216,035
227,095
209,577
372,400
390,774
290,848
474,304
270,824
337,837
298,578
327,547
337,890
403,584
339,447
402,300
331,119
449,812
323,904
385,072
2,310
2,310385,072323,904449,812331,119402,300339,447403,584337,890327,547298,578337,837270,824474,304290,848390,774372,400209,577227,095216,03575,869140,345101,290111,479138,795112,732122,057118,49899,33776,30667,23289,50298,060152,99794,28394,680118,995100,674124,767113,126227,589210,563106,705236,206240,400173,403175,92840,74556,14237,51092,68082,44090,69331,52023,30423,33229,21428,68124,03826,75120,6768,389
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
167,175
102,914
74,382
115,358
108,800
288,765
314,829
214,808
142,390
69,563
54,880
47,844
192,647
227,150
172,648
168,881
150,357
152,259
197,053
206,441
206,441197,053152,259150,357168,881172,648227,150192,64747,84454,88069,563142,390214,808314,829288,765108,800115,35874,382102,914167,175000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
15,445
14,222
11,778
9,945
3,000
7,278
3,000
7,120
8,470
8,292
9,314
9,136
87,043
26,592
21,911
21,336
22,542
21,941
21,489
20,871
20,658
70,332
22,495
44,025
22,415
21,606
20,928
20,083
19,361
18,549
23,408
24,817
24,844
24,460
23,579
22,800
21,720
20,845
19,968
19,393
18,243
14,365
13,190
12,334
13,940
13,177
12,191
10,905
13,315
0
63,166
62,025
0
062,02563,166013,31510,90512,19113,17713,94012,33413,19014,36518,24319,39319,96820,84521,72022,80023,57924,46024,84424,81723,40818,54919,36120,08320,92821,60622,41544,02522,49570,33220,65820,87121,48921,94122,54221,33621,91126,59287,0439,1369,3148,2928,4707,1203,0007,2783,0009,94511,77814,22215,445000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
215,140
220,103
228,795
231,200
235,209
240,442
125,310
126,951
125,591
128,937
81,749
85,910
89,728
94,542
62,526
65,839
73,335
57,236
63,374
65,277
67,789
67,310
0
067,31067,78965,27763,37457,23673,33565,83962,52694,54289,72885,91081,749128,937125,591126,951125,310240,442235,209231,200228,795220,103215,140000000000000000000000000000000000000000
> Total Stockholder Equity
64,253
107,647
137,789
153,036
512,937
525,079
536,076
537,966
546,103
559,798
580,241
598,594
611,960
624,388
641,878
639,823
652,338
659,800
680,953
678,768
1,080,900
1,098,165
1,077,342
990,915
999,225
994,078
998,895
980,665
983,175
1,640,386
1,661,900
1,652,160
1,663,754
1,626,444
1,648,116
1,684,494
1,711,010
1,691,510
1,711,543
1,691,082
1,704,380
1,699,543
1,716,992
1,714,442
1,730,809
1,555,994
1,557,624
1,507,717
1,515,858
1,171,321
2,292,939
2,276,425
2,264,002
2,156,345
2,129,942
2,107,274
2,139,993
2,124,446
2,122,939
2,072,336
2,072,121
2,080,652
2,080,6522,072,1212,072,3362,122,9392,124,4462,139,9932,107,2742,129,9422,156,3452,264,0022,276,4252,292,9391,171,3211,515,8581,507,7171,557,6241,555,9941,730,8091,714,4421,716,9921,699,5431,704,3801,691,0821,711,5431,691,5101,711,0101,684,4941,648,1161,626,4441,663,7541,652,1601,661,9001,640,386983,175980,665998,895994,078999,225990,9151,077,3421,098,1651,080,900678,768680,953659,800652,338639,823641,878624,388611,960598,594580,241559,798546,103537,966536,076525,079512,937153,036137,789107,64764,253
   Common Stock
25,490
68,500
68,500
68,500
91,500
91,500
91,500
91,500
91,500
91,500
91,500
91,500
183,000
183,000
183,000
183,000
183,000
183,000
183,000
183,000
201,794
201,794
201,794
201,794
201,794
201,794
201,794
201,794
201,794
225,623
225,623
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
812,241
1,055,911
1,055,911
1,055,911
1,055,911
1,055,911
1,055,911
1,055,911
1,055,911
1,055,911
1,055,911
1,055,911
0
01,055,9111,055,9111,055,9111,055,9111,055,9111,055,9111,055,9111,055,9111,055,9111,055,9111,055,911812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241812,241225,623225,623201,794201,794201,794201,794201,794201,794201,794201,794201,794183,000183,000183,000183,000183,000183,000183,000183,00091,50091,50091,50091,50091,50091,50091,50091,50068,50068,50068,50025,490
   Retained Earnings 
29,396
8,858
35,836
48,989
59,328
69,971
80,968
82,858
90,994
100,352
120,795
139,149
152,515
158,717
176,207
174,152
186,668
189,754
210,907
208,723
214,506
228,488
235,005
210,690
219,001
244,928
250,594
235,815
238,846
245,361
264,607
255,119
269,709
229,780
251,652
232,603
250,231
244,729
290,292
284,873
304,141
302,120
269,116
269,791
286,159
98,505
90,385
49,790
58,438
-271,325
-222,418
-238,932
-251,355
-358,523
-384,927
-407,595
-374,876
-406,212
-409,846
-460,269
-460,485
-468,930
-468,930-460,485-460,269-409,846-406,212-374,876-407,595-384,927-358,523-251,355-238,932-222,418-271,32558,43849,79090,38598,505286,159269,791269,116302,120304,141284,873290,292244,729250,231232,603251,652229,780269,709255,119264,607245,361238,846235,815250,594244,928219,001210,690235,005228,488214,506208,723210,907189,754186,668174,152176,207158,717152,515139,149120,795100,35290,99482,85880,96869,97159,32848,98935,8368,85829,396
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,745
7,996
4,708
3,230
5
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000453,2304,7087,99610,745000000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue895,593
Cost of Revenue-274,678
Gross Profit620,914620,914
 
Operating Income (+$)
Gross Profit620,914
Operating Expense-940,736
Operating Income-45,143-319,821
 
Operating Expense (+$)
Research Development99,810
Selling General Administrative508,561
Selling And Marketing Expenses0
Operating Expense940,736608,372
 
Net Interest Income (+$)
Interest Income34,636
Interest Expense-12,471
Other Finance Cost-123
Net Interest Income22,042
 
Pretax Income (+$)
Operating Income-45,143
Net Interest Income22,042
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,594-45,143
EBIT - interestExpense = -12,471
-8,927
3,544
Interest Expense12,471
Earnings Before Interest and Taxes (EBIT)016,066
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax3,594
Tax Provision-13,612
Net Income From Continuing Ops-10,018-10,018
Net Income-8,927
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-22,042
 

Technical Analysis of Chongqing Lummy Pharmaceutical
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Chongqing Lummy Pharmaceutical. The general trend of Chongqing Lummy Pharmaceutical is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Chongqing Lummy Pharmaceutical's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Chongqing Lummy Pharmaceutical.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3 < 3 < 3.17.

The bearish price targets are: 2.45 > 2.03.

Tweet this
Chongqing Lummy Pharmaceutical Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Chongqing Lummy Pharmaceutical. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Chongqing Lummy Pharmaceutical Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Chongqing Lummy Pharmaceutical. The current macd is -0.08929937.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Chongqing Lummy Pharmaceutical price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Chongqing Lummy Pharmaceutical. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Chongqing Lummy Pharmaceutical price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Chongqing Lummy Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) ChartChongqing Lummy Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Chongqing Lummy Pharmaceutical. The current adx is 30.30.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Chongqing Lummy Pharmaceutical shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Chongqing Lummy Pharmaceutical Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Chongqing Lummy Pharmaceutical. The current sar is 2.46188.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Chongqing Lummy Pharmaceutical Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Chongqing Lummy Pharmaceutical. The current rsi is 41.52. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Chongqing Lummy Pharmaceutical Daily Relative Strength Index (RSI) ChartChongqing Lummy Pharmaceutical Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Chongqing Lummy Pharmaceutical. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Chongqing Lummy Pharmaceutical price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Chongqing Lummy Pharmaceutical Daily Stochastic Oscillator ChartChongqing Lummy Pharmaceutical Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Chongqing Lummy Pharmaceutical. The current cci is -64.57496224.

Chongqing Lummy Pharmaceutical Daily Commodity Channel Index (CCI) ChartChongqing Lummy Pharmaceutical Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Chongqing Lummy Pharmaceutical. The current cmo is -19.22526973.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Chongqing Lummy Pharmaceutical Daily Chande Momentum Oscillator (CMO) ChartChongqing Lummy Pharmaceutical Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Chongqing Lummy Pharmaceutical. The current willr is -63.07692308.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Chongqing Lummy Pharmaceutical is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Chongqing Lummy Pharmaceutical Daily Williams %R ChartChongqing Lummy Pharmaceutical Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Chongqing Lummy Pharmaceutical.

Chongqing Lummy Pharmaceutical Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Chongqing Lummy Pharmaceutical. The current atr is 0.13201241.

Chongqing Lummy Pharmaceutical Daily Average True Range (ATR) ChartChongqing Lummy Pharmaceutical Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Chongqing Lummy Pharmaceutical. The current obv is 158,680,968.

Chongqing Lummy Pharmaceutical Daily On-Balance Volume (OBV) ChartChongqing Lummy Pharmaceutical Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Chongqing Lummy Pharmaceutical. The current mfi is 34.29.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Chongqing Lummy Pharmaceutical Daily Money Flow Index (MFI) ChartChongqing Lummy Pharmaceutical Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Chongqing Lummy Pharmaceutical.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Chongqing Lummy Pharmaceutical Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Chongqing Lummy Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.521
Ma 20Greater thanMa 502.880
Ma 50Greater thanMa 1002.836
Ma 100Greater thanMa 2003.244
OpenGreater thanClose2.660
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Chongqing Lummy Pharmaceutical with someone you think should read this too:
  • Are you bullish or bearish on Chongqing Lummy Pharmaceutical? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Chongqing Lummy Pharmaceutical? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Chongqing Lummy Pharmaceutical

I send you an email if I find something interesting about Chongqing Lummy Pharmaceutical.


Comments

How you think about this?

Leave a comment

Stay informed about Chongqing Lummy Pharmaceutical.

Receive notifications about Chongqing Lummy Pharmaceutical in your mailbox!